Contact this trialFirst, we need to learn more about you.
Monoclonal Antibodies
CC-99712 for Multiple Myeloma
Recruiting1 awardPhase 1
Toronto, Ontario
This trial is testing a new drug, CC-99712, for safety and effectiveness in people with multiple myeloma who have relapsed or are refractory to other treatments. The trial will have two parts: dose escalation and expansion. The first part will test different doses of the drug to find the maximum tolerated dose. The second part will test the safety and efficacy of the drug at or below the maximum tolerated dose in a larger group of people.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.